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Abstract
Imaging in neuro-oncology clinical trials can be used to validate patient eligibil-
ity, stage at presentation, response to therapy, and radiation therapy. A number 
of National Clinical Trials Network trials illustrating this are presented. Through 
the Imaging and Radiation Oncology Core’s quality assurance processes for data 
acquisition and review, there are uniform data and imaging sets for review. Once 
the trial endpoints have been analyzed and published, the clinical trial informa-
tion including pathology, imaging, and radiation therapy objects can be moved to 
a public archive for use by investigators interested in translational science and the 
application of new informatics tools for trial analysis.
Keywords: imaging, radiation therapy, clinical trials, targeted therapy,  
cancer treatment
1. Introduction
Over the past three decades, imaging has become an important component of 
successful execution and completion of clinical trials for the National Clinical Trials 
Network (NCTN) of the National Cancer Institute (NCI). Imaging used in clinical 
trials serves as a biomarker to validate patient eligibility, stage at presentation, and 
response to therapy. Once archived, imaging becomes an inexhaustible resource 
to compare response to historical standards and validate tools for analysis of trial 
outcome. The quality of the imaging archive is essential to the NCTN and clinical 
translational investigators. Data acquisition and management quality assurance 
processes are imbedded in trials to ensure that the required trial-specific imaging 
is collected and organized according to standards. Modern neuro-oncology clinical 
trials use anatomic and metabolic imaging with sequences and quality standards 
specific to each clinical trial charter. In this manuscript, we will review the history 
of imaging in clinical trials and the current status of neuro-oncology imaging in 
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the NCTN. Future initiatives and vision for image integration with subject-specific 
biomarkers in neuro-oncology trials will be presented.
2. History of imaging in the NCTN
There is a rich history of clinical trial development within the NCI’s clinical trials 
network. In the early development of the cooperative group clinical trials program, 
emphasis was placed on clinical protocols with onsite physician assessment of 
response and site-associated application of radiation therapy treatment objects. 
Even in trials that required radiation therapy, little information was made available 
to the clinical trial investigators concerning the abnormality defined on imaging, 
choice of area treated with radiation therapy, and dose to target. Because computa-
tional algorithms for dose calculation were varied and driven in part by individual 
institutional structure and process, the initial quality assurance processes in 
radiation oncology placed emphasis on creating uniformity of these processes with 
less emphasis on imaging and the application of imaging to target. By 1972, com-
mittees in the cooperative groups identified mechanisms to acquire information 
about targets treated. This included review of radiation therapy kilovoltage (kV) 
simulation images and megavoltage (MV) therapy portal images to confirm that 
what was intended to be delivered was treated. The trial-required information had 
to be forwarded to quality assurance centers as hard copies, where it was reviewed 
for trial compliance. These quality assurance reviews were performed largely in ret-
rospect, as trials reached closure, due to the cumbersome data submission process. 
As the data acquisition processes became more familiar to investigators, efforts were 
made to review hard copy objects early in the radiation treatment process to ensure 
that the treatment plan met study guidelines [1, 2].
By 1980, three-dimensional volumetric radiation therapy treatment planning 
was being introduced to clinical trials as well as using electronic media to transmit 
data. The initial effort in volumetric electronic data collected placed emphasis on 
prostate carcinoma; however, the importance of imaging in the quality review 
process for radiation oncology began to become more visible and prominent in 
multiple disease sites including lymphoma. In the Pediatric Oncology Group (POG) 
protocol 8725, the objectives of the study were to randomize the role of radiation 
therapy in what would be called intermediate to advanced stage subjects by modern 
standards. The subjects received eight cycles of hybrid chemotherapy and are then 
randomized to receive radiation therapy to all initial sites of disease or complete 
their care without radiation. In the initial publication of the trial, there was no 
added benefit to the addition of radiation therapy to this population of subjects. 
However, in a subset analysis, those subjects that were treated by study standards 
and had all sites of disease treated at presentation had a 10% statistically significant 
disease-free survival benefit [3]. In other words, excluding sites of original disease 
was detrimental to outcome. Imaging was essential to this interpretation as well 
as the application of diagnostic imaging to radiation therapy treatment execution. 
This was one of the first trials that acquired imaging both at baseline and at closure 
of chemotherapy as radiation therapy targets had to be designed to imaging param-
eters and sites of disease at presentation with response-adapted blocking applied to 
mediastinal disease. Without imaging submitted for trial review, this interpretation 
could not be made. Today the partnership between imaging and radiation therapy is 
synergistic, and radiation therapy is fully dependent on image-guided platforms for 
modern patient care [4, 5].
The next iteration of Hodgkin lymphoma studies evaluated both early stage 
and intermediate stage subjects with response-adapted treatment. Because of the 
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non-compliant radiation therapy issues in POG 8725, the imaging and the radiation 
therapy treatment objects, as based on the disease at presentation, were reviewed by 
the Quality Assurance Review Center (QARC) before the start of radiation therapy. 
Pre- and post-chemotherapy imaging were reviewed to assess radiation therapy 
compliance. Compliance to radiation therapy was achieved; however, retrospective 
analysis of imaging response to chemotherapy demonstrated that central review 
disagreed with site assessment on 50% of cases [6]. Therefore, in the next itera-
tion of trials evaluating intermediate risk subjects, imaging and radiation therapy 
objects were reviewed through a central mechanism in real-time pre-therapy, post 
two cycles of chemotherapy, post all chemotherapy, and pre-radiation therapy to 
ensure that response assessment was consistent with study objectives and radiation 
therapy was applied uniformly throughout the trial. Children’s Oncology Group 
(COG) trial AHOD0331 accrued more than 1700 subjects and demonstrated that 
both anatomic and metabolic imaging and radiation therapy objects could be 
reviewed in an electronic format in real time at multiple study endpoints and permit 
adaptive therapy based on response to treatment. This infrastructure provided 
a platform to emphasize the importance of imaging in clinical trials as well as a 
mechanism to use imaging as a validation vehicle for successful execution of clinical 
trials. Because imaging can be simultaneously reviewed by multiple individuals 
including site and study investigators in real time, consensus between investigators 
could reach closure in a timely manner. Subject-specific issues and optimization of 
clinical trial management were addressed in a uniform manner and as early as the 
subject was enrolled on the trial [5, 7, 8].
The informatics platform quickly matured to support imaging in all pediatric 
and adult oncology radiology and radiation therapy disease service areas including 
neuro-oncology with real-time review of imaging objects to ensure study compli-
ance. Protocols for standard risk medulloblastoma originating in the posterior 
fossa require no more than 1.5 cm3 of residual disease and no evidence of disease 
on spine imaging at presentation. These objects are reviewed immediately in real 
time prior to subject entry onto study to ensure that the subject has entered onto 
the appropriate study and staged in a manner consistent with study objectives. 
Studies have confirmed that high-risk medulloblastoma patients unintentionally 
entered on low-risk studies have a significantly worse outcome, thus obfuscat-
ing interpretation of the study when evaluated on an intent to treat basis [9]. 
Completeness of resection is reviewed in real time for patients with ependymoma 
to ensure that the sequence of care including second surgical procedure as required 
by study is consistent with study guidelines. These changes in process serve to 
improve the quality of the study and are adjudicated by imaging. Imaging is identi-
fied as an essential component to successful clinical trial execution and by 1996 
became well positioned to be recognized as a strong and independent discipline in 
the national clinical trials effort [3].
In 1997, Robert Wittes, MD, was the director of the Cancer Treatment Evaluation 
Program (CTEP) and recognized the need to develop an imaging program in clini-
cal trials to function at an enterprise level. The NCI established a cancer imaging 
program under the direction of Daniel Sullivan, MD. In September of 1998, the 
American College of Radiology Imaging Network (ACRIN) was established under 
the direction of Bruce Hillman, MD, and Constantine Gatsonis, PhD. ACRIN had 
significant initial success managing important cancer screening trials including 
the digital mammography imaging screening trial (DMIST) and the National 
Lung Screening Trial (NLST). ACRIN has significant influence in credentialing 
institutions for imaging clinical trial participation and data management of clinical 
trials in all oncology disease areas including neuro-oncology imaging. ACRIN also 
participates in clinical trials including cardiology, interventional radiology, and 
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advanced technology neurological imaging in non-oncology-related areas serving to 
further expand their portfolio and scope of service. ACRIN has partnered with the 
Eastern Clinical Oncology Group (ECOG) to bring its robust imaging infrastructure 
to support activities in a strong cooperative group with multiple disease commit-
tees. As ECOG-ACRIN, a strong standard is established for clinical trial interactions 
between clinical scientists and imaging partners. The imaging information for 
ECOG-ACRIN is managed by the Imaging and Radiation Oncology Core office in 
Philadelphia (IROC Philadelphia).
Of equal strength is the Wright Center of Innovation in Biomedical Imaging at 
the Ohio State University. Under the direction of Michael Knopp, MD, PhD, the 
Wright Center has obtained several major grant awards including a Frontier grant 
from the state of Ohio and a biomedical research and technology transfer award. 
The center houses expertise in microimaging, molecular imaging, animal imaging, 
as well as advanced technology imaging to support clinical trial processes. The 
Wright Center supports all the imaging needs including data management and 
real-time case review for the Alliance and SWOG clinical trial groups including 
significant expertise in neuroimaging and case evaluation. The Wright Center has 
developed processes to track compliance to anatomic and metabolic images acquired 
for clinical trials. The neuro-oncology committees are exceptionally strong, and 
neuro-oncology and neuroimaging are prominent disease-oriented committees in 
these important groups. Lawrence Schwartz, MD directs the imaging committees 
for Alliance and SWOG and works in close collaboration with the Wright Center 
for clinical trial execution. The office managing imaging information at the Wright 
Center for Alliance and SWOG is the Imaging and Radiation Oncology Core at Ohio 
(IROC Ohio).
Formerly known as Quality Assurance Review Center (QARC), the Imaging 
and Radiation Oncology Core center in Rhode Island (IROC RI) is responsible for 
imaging needs in COG. The imaging committee in COG became a formal discipline 
committee at the time of the merger between the Pediatric Oncology Group (POG) 
and Children’s Cancer Group (CCG). QARC worked with committee members to 
establish an informatics infrastructure required for digital image transfer. This 
was accomplished by Keith White, MD, in collaboration with the information 
technology group at QARC. Data acquisition tools were applied to the process that 
he used to acquire and display images for tumor board at his home institution. The 
acquisition process is now synergistic with the data acquisition for radiation therapy 
treatment objects, and these can now be displayed in the IROC RI database for 
remote review of objects in a side-by-side manner by site and study investigators. 
Clinical trial investigators in all clinical disciplines including imaging and radiation 
oncology can review study objects in a harmonized and single-session manner. 
Because clinical trials require real-time review of objects for response assessment-
adaptive clinical trials and the subsequent application of radiation therapy, each 
month, there are hundreds of study investigator logins to assure adaptive trial 
design is met and response/disease progression is noted and assessed in a uniform 
manner (Figure 1). Neuro-oncology imaging is essential to mission for COG as 
brain tumors comprise 25% of pediatric oncology. It is important that all image 
datasets including pre-/post-surgery/therapy and outcome imaging be available for 
review on a real-time basis as needed. The image library housed at IROC RI is the 
largest collection of pediatric oncology imaging in the world on patients treated 
on clinical trials with a complete portfolio of images on neuro-oncology patients 
treated on clinical protocols. The IROC Houston office (formerly the Radiological 
Physics Center (RPC)) works with all radiation oncology discipline committees of 
the NCTN and is the central resource for credentialing institutions for participation 
in clinical trials managed through the NCTN.
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IROC is a single grant with overarching administrative structure to four 
grant offices in Houston TX, Columbus OH, Philadelphia PA, and Lincoln 
RI. Administrative support is provided by the American College of Radiology 
(ACR). IROC provides credentialing and data management for the NCTN in imag-
ing and radiation oncology clinical trial participation (Figure 2). All offices that 
provide imaging data management services are involved in neuroimaging in NCTN 
clinical trials. The offices all collaborate with NCTN investigators to write uni-
form guidelines into all clinical trials involving the central nervous system (CNS) 
to ensure optimal clinical trial management and uniform response assessment. 
Modern guidelines include sequence acquisition requirements, slice thickness, 
and other acquisition parameters, which are written into every protocol by study 
investigators and IROC. The guidelines support both pediatric and adult clinical 
trials in neuro-oncology.
Figure 1. 
Number of remote NCTN reviewer logins to terminal servers 2007–2019. Image courtesy of QARC.
Figure 2. 
NCI National Clinical Trials Network Structure. IROC is within the NCTN centralized functions. Image 
courtesy of the National Cancer Institute.
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3. The importance of imaging applications in radiation therapy
Imaging platforms have become essential to daily operation in radiation oncol-
ogy. From initial assessment of imaging for target definition to daily treatment 
alignment with cone beam computed tomography (CT), imaging has become an 
essential component of the infrastructure to successful delivery of daily radiation 
therapy. Imaging has likewise become essential for credentialing institutions to par-
ticipate in clinical trials involving the CNS including the use of phantom technology 
for CNS magnetic resonance imaging (MRI) and application of radiation therapy. 
In an early iteration of the use of imaging as a credentialing vehicle, institutions 
received a planning image with a right temporal target and were asked to develop a 
therapy plan using a vertex field. This evaluated the ability of the institution to use 
three-dimensional modeling for therapy planning. Most radiation therapy planning 
systems are based on CT obtained in the therapy position with the appropriate 
immobilization device. CT, however, has significant limitations in defining targets 
for radiation therapy for lesions in the CNS. For clinical trials involving stereotactic 
radiosurgery (SRS), a credentialing vehicle was constructed where an institution 
would receive a planning CT with SRS coordinates. The target lesion was not visible 
on CT. An MR with a visible single lesion was provided, and the institution had to 
fuse the images into the site radiation planning system and provide x, y, and z coor-
dinates for a stereotactic procedure [10]. The high-resolution and reality imaging 
registration processing evaluates both fusion tools and treatment planning capabili-
ties. Anthropomorphic phantom tools have been developed by the IROC Houston 
office that require image validation for target definition as part of the credentialing 
process. This cross-validation has been essential for both documentation of image 
and assessment of the site computational planning algorithms (Figure 3).
Because tumors of the central nervous system are better defined with advanced 
technology imaging including advanced MR sequences and spectroscopy, fusion 
of images in treatment planning CT is a great resource and significantly improves 
target definition and patient care. In current NCTN protocols, advanced MR 
sequences are integrated with new positron emission tomography tracers including 
amino acid imaging and spectroscopy to create multiple target volumes treated with 
dose painting to areas of sequence abnormality. This is of increasing importance. 
Historically, neurosurgeons would remove regions of contrast enhancement seen on 
Figure 3. 
Phantom tool developed by IROC Houston used in the RT site credentialing process. 1520 RT sites have passed at 
least one irradiation of this phantom. Image courtesy of IROC Houston.
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CT and limited MR signal changes. Radiation oncologists, even on study, often treat 
the surgical resection site with a margin. With more primitive anatomical imaging, 
radiation oncologists performed poorly in defining the target volume of interest 
and may have not treated the entire tumor volume at risk on historical studies. New 
imaging models including amino acid imaging are demonstrating regions of tumor 
proliferation and tumor DNA synthesis which have been less visible and as a result, 
undertreated by radiation oncology. In primary brain patients, Investigators have 
confirmed that disease can reside in regions of FLAIR enhancement, thus influenc-
ing the choice of radiation therapy field placement. Spectroscopy may likewise be 
helpful moving forward in better defining targets at risk, and this is currently under 
evaluation with dose painting clinical trials in glioblastoma. Several papers have 
interesting reviews evaluating patterns of failure [11, 12]. In patients whose disease 
abutted central structures including the corpus callosum, failure patterns followed 
major nerve pathways into the contralateral hemisphere. If the anatomic and 
metabolic tumor target could be more optimally defined at presentation, we would 
potentially treat the patient more effectively with radiation therapy, hence possibly 
improving outcomes, as there is a high index of suspicion that simply targeting 
the region of contrast enhancement with margin may be insufficient for radiation 
therapy. Current protocols are using advanced imaging tools for target definition 
and dose painting. The volumes treated between T2 and FLAIR imaging were very 
different. Accordingly, the radiation fields are larger than targeting areas of contrast 
enhancement, and it will be important to monitor toxicity and pattern of failure 
with biomarker analysis [13].
Outcome imaging is important in clinical trials and often requires central review 
of imaging objects to provide consistent interpretation of treatment effect and 
disease progression. This is essential as often changes seen on MRI post-therapy 
can mimic disease progression. The NCTN pediatric and adult oncology databases 
include subjects with disease of the CNS including spine. These databases store 
imaging at presentation, pre- and post-surgery, radiation therapy treatment objects, 
and post-therapy. Because these images were obtained on study, the sequences 
and time points of data acquisition post-therapy are uniform in acquisition. These 
become optimal datasets for the development of machine learning and artificial 
intelligence tools to better evaluate this dilemma. The databases are linked to 
outcome through the statistical centers of each of the network groups and therefore 
are an invaluable resource to the field of neuro-oncology [9].
4. Current portfolio for neuro-oncology analysis in IROC
The Imaging and Radiation Oncology Core (IROC) houses all diagnostic imag-
ing and radiation therapy treatment objects on subjects treated on clinical trials for 
the NCTN. The IROC office in RI works with the Children’s Oncology Group (COG) 
and houses objects on subjects treated on clinical trials for more than 35 years. IROC 
RI also houses radiation therapy treatment objects for SWOG, Alliance, and ECOG-
ACRIN. Trials include management of standard and high-risk medulloblastoma, 
ependymoma, primitive neuroendocrine tumors, germ cell tumors, and low-/
high-grade glioma. Trials have studied the addition of chemotherapy to radiation 
therapy in multiple disease sites, sequence of management, and drug X-ray dose 
titration/augmentation. Modern protocols have applied adaptive strategies to titrate 
therapy to younger population, limit radiation boost dose to lesions that undergo 
gross tumor resection, and alter therapeutic application to medulloblastoma 
relative to tumor gene expression profiles. The IROC Ohio office manages neuro-
oncology imaging for SWOG and Alliance. The Alliance group has an exceptionally 
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strong neuro-oncology committee with primary emphasis in developing clinical 
trials for adult glioblastoma including studies directed to new modalities of care 
integrated with modern genomics and gene expression profiles. The IROC office 
in Philadelphia integrates the imaging strengths of imaging with ACRIN and the 
radiation oncology strengths of NRG (former NSABP, RTOG, and GOG). The 
emphasis of these groups is in the application of modern radiation oncology tech-
nology coupled with biomarker-driven applied chemo/targeted therapy for adult 
glioblastoma. Currently, IROC RI houses information on 24 protocols with datasets 
on over 3000 patients including imaging at presentation, post-therapy, relapse, and 
radiation therapy treatment objects for pattern of failure analysis. These include 
studies on primitive neuroectodermal disease, germ cell disease, high-/low-grade 
glioma, atypical rhabdoid lesion, medulloblastoma, and ependymoma. IROC Ohio 
houses images on more than 2000 patients treated for glioblastoma as well as images 
on protocols treating meningioma. The protocols include patients treated with 
vaccine therapy, antiangiogenetic therapy, and poly ADP ribose polymerase (PARP) 
inhibitors in patients with O[6]-methylguanine-DNA methyltransferase (MGMT) 
promotor hypermethylation as well as studies evaluating anaplastic and/or low-
grade glioma treated with adjuvant PCV chemotherapy including those with 1p/19q 
co-deletions. IROC Philadelphia manages a similar volume of patients on study 
treated for glioblastoma with emphasis on radiation therapy target definition and 
technique. Each of the IROC centers manages advanced technology-driven imaging 
for radiosurgery for central nervous system metastatic disease. Neuro-oncology 
protocols managed by each of the IROC offices and available datasets are used for 
secondary clinical translational research objectives.
In the next generation of translational research for neuro-oncology, integration 
of biomarkers including genomics and applied gene expression profiles will need 
to be coupled with radiomics integrated with radiation therapy treatment plans. 
Ex vivo tissue unfortunately is an exhaustible resource and needs to be preserved 
for unanticipated biomarker evaluation in addition to current portfolios. Digital 
quantitative pathology will play an important role to integrate established and vali-
dated non-imaging biomarkers and biomarker processes with microscopy imaging 
signals to better predict outcome. Saltz and colleagues have integrated pathology 
biomarkers with imaging signals. Erickson and colleagues have identified radiomic 
signatures in glioblastoma patients that indicate and predict gene expression and 
methylation. Harmonization of this effort at an enterprise level will be the next step 
in developing improved tools for translational science [14–19].
5. The Cancer Imaging Archive (TCIA)
The Cancer Imaging Archive is a collaboration of many key investigators with 
Fred Prior, PhD (University of Arkansas), as the principal investigator. Processes 
within the NCTN clinical trial groups serve to protect all information of subjects 
participating on clinical trials including their tissue, imaging, and radiation therapy 
treatment objects. Once a trial has completed accrual and primary endpoints have 
been recognized and published, an important objective of the National Cancer 
Institute is to move study information to a public archive for use by all interested 
in translational science and application of new informatics tools for trial analysis. 
The objective is for all important material including tissue biomarkers and outcome 
information be available to investigators. TCIA has a strong infrastructure with 
expertise in informatics science, imaging, digital pathology, and clinical trial man-
agement. The archive currently houses a diverse portfolio of studies and is poised 
to function at an enterprise level to support translational science improvement. The 
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current portfolio of studies accessible through the TCIA includes studies involv-
ing low- and high-grade glioma with associated pathology. Over 1000 datasets are 
available on 11 studies. TCIA will be an invaluable resource for future translational 
science in neuro-oncology [20, 21]. Cancers of all disease types will be made avail-
able to investigators worldwide through this mechanism.
6. Conclusions
Neuro-oncology is an increasingly important component in the care of patients 
with cancer. Both primary lesions and metastatic disease affect a significant seg-
ment of the pediatric and adult populations. The care of these patients requires 
extended healthcare system resources for physician expertise and para health 
professionals for supportive and rehabilitative care. Progress will be made by opti-
mizing uniform applications of imaging both at disease presentation and response 
to therapy. Informatics processes are established in the NCTN and the TCIA to help 
move this forward for patients afflicted with CNS disease. Information from trials 
will be available in a public TCIA archive to help investigators perform translational 
research through this mechanism and accelerate progress in this field.
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